<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Approach to Thalassemia in Primary Health Care (PHC)</title>
<style>
  body { font-family: Arial, sans-serif; line-height: 1.6; margin: 40px; background-color: #fafafa; color: #333; }
  h1, h2, h3 { color: #004d66; }
  ul, ol { margin-left: 20px; }
  table { width: 100%; border-collapse: collapse; margin: 20px 0; }
  th, td { border: 1px solid #ccc; padding: 10px; text-align: left; }
  th { background-color: #e0f0f5; }
  a { color: #006699; text-decoration: none; }
  a:hover { text-decoration: underline; }
</style>
</head>
<body>

<h1>Approach to Thalassemia in Primary Health Care (PHC)</h1>

<h2>1. Initial Assessment</h2>
<ul>
  <li>Obtain detailed family and ethnic history (Mediterranean, Asian, or African ancestry increases risk).</li>
  <li>Perform complete blood count (CBC) and peripheral smear.</li>
  <li>Identify microcytic anemia with normal or elevated ferritin levels (helps differentiate from iron deficiency).</li>
  <li>If thalassemia suspected, refer for hemoglobin electrophoresis or genetic testing.</li>
</ul>

<h2>2. Counseling and Screening</h2>
<ul>
  <li>Provide <strong>genetic counseling</strong> to patients and families.</li>
  <li>Screen family members and reproductive partners for thalassemia carrier status.</li>
  <li>Preconception counseling for at-risk couples to prevent major thalassemia births.</li>
</ul>

<h2>3. Management in PHC</h2>

<h3>Thalassemia Minor (Trait)</h3>
<ul>
  <li>Usually <strong>no treatment</strong> required.</li>
  <li>Educate patients to avoid unnecessary iron supplementation unless iron deficiency confirmed.</li>
  <li>Prescribe <strong>folic acid supplementation</strong> during pregnancy or intercurrent illness.</li>
</ul>

<h3>Thalassemia Intermedia and Major</h3>
<ul>
  <li><strong>Transfusion therapy</strong> is the mainstay for moderate to severe cases.</li>
  <li>Indications:
    <ul>
      <li>Hemoglobin (Hb) < 7 g/dL or clinical symptoms (fatigue, poor growth).</li>
      <li>Target Hb: maintain 9–10 g/dL.</li>
    </ul>
  </li>
  <li><strong>Iron overload management:</strong> chelation therapy with agents such as <em>deferasirox</em> when ferritin ≥ 1000 µg/dL.</li>
  <li>Monitor for complications: gallstones, splenomegaly, bone deformities.</li>
  <li>Refer to tertiary care for:
    <ul>
      <li>Persistent anemia or iron overload despite treatment.</li>
      <li>Splenectomy consideration for hypersplenism or massive splenomegaly.</li>
      <li>Hematopoietic stem cell transplantation or gene therapy evaluation (curative potential).</li>
    </ul>
  </li>
</ul>

<h3>Supportive Care</h3>
<ul>
  <li>Provide <strong>routine immunizations</strong> (especially post-splenectomy).</li>
  <li>Encourage <strong>balanced nutrition</strong> and folate-rich diet.</li>
  <li>Monitor for endocrinopathies, diabetes, and cardiac complications in long-term follow-up.</li>
</ul>

<h2>4. Special Situations</h2>

<h3>Pregnancy</h3>
<ul>
  <li>High-risk pregnancy—refer to specialist care early.</li>
  <li>Preconception genetic counseling is essential.</li>
  <li>Maintain Hb > 10 g/dL to prevent intrauterine growth restriction.</li>
  <li>Use <em>deferoxamine</em> (chelation) only in 2nd and 3rd trimesters.</li>
</ul>

<h3>Post-Splenectomy Care</h3>
<ul>
  <li>Vaccinate against pneumococcus, meningococcus, and Haemophilus influenzae type B.</li>
  <li>Educate regarding risk of overwhelming post-splenectomy sepsis (OPSI).</li>
  <li>Consider lifelong antibiotic prophylaxis as per protocol.</li>
</ul>

<h2>5. Referral Criteria from PHC</h2>
<ul>
  <li>Severe anemia unresponsive to standard management.</li>
  <li>Progressive splenomegaly.</li>
  <li>Iron overload complications (liver, cardiac involvement).</li>
  <li>Pregnancy in thalassemia major or intermedia.</li>
</ul>

<h2>6. Patient Education and Follow-Up</h2>
<ul>
  <li>Emphasize the genetic nature of the disease.</li>
  <li>Encourage regular follow-up every 3–6 months.</li>
  <li>Advise avoiding unnecessary iron therapy unless iron deficiency is proven.</li>
</ul>

<hr>
<h3>References</h3>
<ol>
  <li><a href="https://www.amboss.com/us/knowledge/thalassemia?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">Thalassemia – AMBOSS</a></li>
</ol>

</body>
</html>
